Novartis psoriasis treatment shows strong results
Basel – Novartis’ Cosentyx has proven highly effective against psoriasis. The skin condition can cause psychological problems for many patients and can be very difficult to treat.
Psoriasis healing on palms. (Img: Novartis AG)
The Basel pharmacetical company Novartis has released the latest data showing that its treatment Cosentyx delivers high and long-lasting skin clearance in patients with plaque psoriasis. Over the course of a 4-year study, patients were treated with Cosentyx. 68.5 per cent of them had clear or almost clear skin after the first year, and this high rate was maintained through to the fourth year. 43.8 per cent of the patients achieved completely clear skin.
The study also looked at the long-term efficacy of Cosentyx in treating psoriasis of the hands and feet, long considered difficult areas to treat on the body. The Novartis treatment was equally effective in this regard: approximately 60 per cent of patients achieved clear or almost clear palms and soles with Cosentyx. These results continued to improve over 1.5 years.
Novartis also published the results of a global survey on psoriasis patients. It shows that 57 per cent of the 8,300 patients surveyed have not achieved clear skin with standard treatments. Many of those surveyed said that they do not believe they will ever achieve clear skin. A total of 84 per cent of those surveyed said they face discrimination and humiliation, and 38 per cent said they have been diagnosed with a psychological condition due to their psoriasis.
Novartis is keen to remedy this situation and supports the World Health Organization’s resolution to make psoriasis a global health priority. Cosentyx is already approved in many countries to treat plaque psoriasis, psoriasis arthritis and ankylosing spondylitis.
Share this article
You might also be interested in
The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...Read More
Startups from the Basel Area have been ranked highly in the TOP 100 Swiss Startup Award by Venturelab. The medtech...Read More
The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that...Read More
The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research...Read More
The Basel Area-based company Polyphor has signed an exclusive licensing agreement with Fosun Pharma in China. Fosun Pharma will lead...Read More
With the new “swiss hosting” label, the Basel-based company swiss made software Gmbh is guaranteeing that data will not be...Read More
Karin Crisanto recently joined Basel Area Business & Innovation as Head of Innovation Space and Infrastructure. She previously worked for...Read More